Authors
Latest:
Patient Input and Patient Preference StudiesPatient preferences are increasingly seen as valuable in healthcare policy decision-making, but such studies are not always easy to design and implement, writes Nick Hicks.
Latest:
How Pharma’s Checks and Balances Can Help Fight Its Public PerceptionWhat can we do to prevent such blatant black eyes to the industry so many of us love?
Latest:
Legal: Foreign PolicyCompliance requires overcoming cultural barriers. To start with, in some countries the taboo against bribery is not as strong as it is here.
Latest:
Finding the Translators: Helping Connect the Science to the PatientThe need for analytics translators is not limited to data science. The adoption of all scientific or technical advances, including those in the healthcare industry, needs effective translators. So what does this mean for pharma marketing?
Latest:
Ten Minutes to ConnectHow one conversation between a woman and her physician can make or break a brand
Latest:
The Road to Nowhere?Drug companies can do to specialists what Intel did to PC box makers: commoditize them.
Latest:
Introduction: Minding MoralsWHEN I WAS GROWING UP, my favorite book was Aesop's Fables. I especially loved the way every story had a moral at the end to tie everything together: Try before you trust; the hero is brave in deeds as well as words; birds of a feather flock together; might makes right; don't be the boy who cried wolf. Those one-line messages packed a punch then, and still stick with me.
Latest:
Exponential Medicine and Pharma's Unfulfilled PromiseBill Drummy reviews the "techno-optimistic" highlights of this year's Exponential Medicine conference in San Diego.
Latest:
Navigating Divergent Currents: Biopharma Review and OutlookDespite steady innovation and solid new drug approvals, the first half of 2025 was marked by a break from historical norms in financing, stock performance, and M&A for the pharma and biotech sectors.
Latest:
Track Patients, Not PrescriptionsEven though data can single out physicians with high marketing upsides, most pharma companies are doing without such high-value data.
Latest:
Meetings: Doctor ConsultationMeetings at which peripheral activities become the focal point are likely to attract scrutiny.
Latest:
A New Game Plan for Pharma HRNew dynamics are forcing the industry's human resource departments to rethink their operational game plans. The drivers-consolidation, globalization, scientific advances, public policy, and competition-have pushed HR leaders into new territory to address business needs.
Latest:
Sampling: Crimes in the ClosetThe pharmaceutical industry devotes more of its promotional budget to samples than anything else, unless you count the army of sales representatives that delivers them. This year, the average wholesale price of samples passed out to doctors will approach $15 billion-roughly twice the value of samples five years ago. And although few in the industry have come to grips with it, the federal regulations governing this enormous investment have undergone drastic changes.
Latest:
Key Opinion Leaders Interactions with PharmaData suggest that pharma companies engage the same key opinion leaders on assignments in three to seven departments or product groups at once.
Latest:
Meeting Unmet Medical Needs: The Disparity DilemmaThe US drug regulatory system fails to address the country’s most urgent medical needs with the resources appropriate for the task. But change is possible, say Christopher-Paul Milne and Kenneth I. Kaitin.
Latest:
Vaccines: Market on the ReboundMergers have cut the field of companies with real marketing and manufacturing muscle from 25 to five. The 2004 vaccine market will double by 2009.
Latest:
Why It’s Time to Get Smarter about Content Management and Document ProductionStructured authoring is an approach that has eluded life sciences, limiting firms’ ability to transform routine regulatory processes. But this could all change, writes Romuald Braun.
Latest:
Knowledge-Based Outsourcing: Driving Deeper InsightsTracking, monitoring, and trend evaluation is not enough. Companies must now do more than assess what happened and why.
Latest:
Protecting IP Throughout the Product LifecycleNow that patents on several blockbuster drugs have expired, the industry-feeling the pinch-has focused its attention on intellectual property. Because every additional month of market exclusivity can mean an extra $50 million or more in revenue, pharma companies have gone to great lengths to block the entry of generic competition.
Latest:
Goodbye, Willy LomanThe days of pharma sales reps going office-to-office with samples and brochures are done. These days, they need to turn their attention to payers, pharmacists, and consumers
